Authors
Bo Tang, Wing Hei Leung, Chihao Shao, Dongfang Li, Kwai Man Lau, Macro K H Lui, Jingyi Liu, Jacky C H Chu, Clare S W Yan, Chi-Ming Che, Xuechen Li, Wing-Tak Wong, Larry Ming Cheung Chow, Terence K W Lee, Clarence T T Wong
Published in
MedComm. Volume 7. Issue 7. Pages e70808. Epub Jun 17, 2026.
Abstract
Bispecific antibodies (BsAbs) represent a growing class of cancer immunotherapeutics, yet their wider adoption remains limited by complex recombinant production and limited manufacturing efficiency. Here, we report a chemically assembled macrophage-engaging glypican-3 × signal regulatory protein-α (SIRP-α) bispecific antibody for the treatment of liver cancer. Using our bifunctional linker, glypican-3-binding peptide dimers were conjugated to a native anti-SIRP-α IgG via a rapid one-pot, two-step process, yielding a novel dendritic bispecific antibody (dBsAb). Such a construct simultaneously targets glypican-3-positive hepatocellular carcinoma cells and blocks the CD47-SIRP-α axis, thereby promoting macrophage engagement and phagocytosis. In vitro studies showed substantially enhanced macrophage adhesion and tumor cell clearance compared with the monoclonal antibody. In an in vivo experiment, dBsAb demonstrated a 68% reduction in tumor growth, with increased macrophage infiltration, M1 polarization, and elevated antigen presentation without observable systemic toxicity. This chemical assembly approach offers a practical alternative to recombinant methods for constructing bispecific antibodies and may facilitate the development of macrophage-directed immunotherapies.
PMID:
42318525
Bibliographic data and abstract were imported from PubMed on 19 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0